201 related articles for article (PubMed ID: 9875577)
1. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment.
Chougnet C; Fowke KR; Mueller BU; Smith S; Zuckerman J; Jankelevitch S; Steinberg SM; Luban N; Pizzo PA; Shearer GM
AIDS; 1998 Dec; 12(18):2397-406. PubMed ID: 9875577
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.
Wintergerst U; Hoffmann F; Sölder B; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH
Pediatr Infect Dis J; 1998 Jun; 17(6):495-9. PubMed ID: 9655541
[TBL] [Abstract][Full Text] [Related]
3. Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
Thuret I; Michel G; Chambost H; Tamalet C; Giraud P; Brunet C; Perrimond H
AIDS; 1999 Jan; 13(1):81-7. PubMed ID: 10207548
[TBL] [Abstract][Full Text] [Related]
4. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
[No Abstract] [Full Text] [Related]
5. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
Bellman PC
AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
[TBL] [Abstract][Full Text] [Related]
7. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease.
Mezzaroma I; Carlesimo M; Pinter E; Alario C; Sacco G; Muratori DS; Bernardi ML; Paganelli R; Aiuti F
AIDS; 1999 Jul; 13(10):1187-93. PubMed ID: 10416521
[TBL] [Abstract][Full Text] [Related]
8. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy.
Mueller BU; Zeichner SL; Kuznetsov VA; Heath-Chiozzi M; Pizzo PA; Dimitrov DS
AIDS; 1998 Oct; 12(15):F191-6. PubMed ID: 9814861
[TBL] [Abstract][Full Text] [Related]
9. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis.
Arribas JR; Hernández-Albujar S; González-García JJ; Peña JM; Gonzalez A; Cañedo T; Madero R; Vazquez JJ; Powderly WG
AIDS; 2000 May; 14(8):979-85. PubMed ID: 10853979
[TBL] [Abstract][Full Text] [Related]
10. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.
Vigano A; Vella S; Saresella M; Vanzulli A; Bricalli D; Di Fabio S; Ferrante P; Andreotti M; Pirillo M; Dally LG; Clerici M; Principi N
AIDS; 2000 Feb; 14(3):251-61. PubMed ID: 10716501
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
[TBL] [Abstract][Full Text] [Related]
12. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
Lederman MM; Connick E; Landay A; Kuritzkes DR; Spritzler J; St Clair M; Kotzin BL; Fox L; Chiozzi MH; Leonard JM; Rousseau F; Wade M; Roe JD; Martinez A; Kessler H
J Infect Dis; 1998 Jul; 178(1):70-9. PubMed ID: 9652425
[TBL] [Abstract][Full Text] [Related]
13. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
14. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages.
Sleasman JW; Nelson RP; Goodenow MM; Wilfret D; Hutson A; Baseler M; Zuckerman J; Pizzo PA; Mueller BU
J Pediatr; 1999 May; 134(5):597-606. PubMed ID: 10228296
[TBL] [Abstract][Full Text] [Related]
15. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.
Li TS; Tubiana R; Katlama C; Calvez V; Ait Mohand H; Autran B
Lancet; 1998 Jun; 351(9117):1682-6. PubMed ID: 9734884
[TBL] [Abstract][Full Text] [Related]
16. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.
Piketty C; Castiel P; Belec L; Batisse D; Si Mohamed A; Gilquin J; Gonzalez-Canali G; Jayle D; Karmochkine M; Weiss L; Aboulker JP; Kazatchkine MD
AIDS; 1998 May; 12(7):745-50. PubMed ID: 9619806
[TBL] [Abstract][Full Text] [Related]
17. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses.
Blazevic V; Jankelevich S; Steinberg SM; Jacobsen F; Yarchoan R; Shearer GM
Clin Diagn Lab Immunol; 2001 Sep; 8(5):943-8. PubMed ID: 11527808
[TBL] [Abstract][Full Text] [Related]
18. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
Al-Harthi L; Siegel J; Spritzler J; Pottage J; Agnoli M; Landay A
AIDS; 2000 May; 14(7):761-70. PubMed ID: 10839583
[TBL] [Abstract][Full Text] [Related]
19. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
20. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS.
Chougnet C; Jankelevich S; Fowke K; Liewehr D; Steinberg SM; Mueller BU; Pizzo PA; Yarchoan R; Shearer GM
J Infect Dis; 2001 Jul; 184(2):201-5. PubMed ID: 11424019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
